top of page

Annarita Miccio

Institut Imagine, Paris

Dr. Miccio’s main interests are the transcriptional control of hematopoiesis, and the development of therapeutic approaches to β-hemoglobinopathies. As a PhD student, she generated a lentiviral vector (LV) successfully used in an early clinical trial for β-thalassemia. As a post-doc and later as an assistant professor, she gained experience in the gene regulation during erythroid development and in evaluating the efficacy of gene therapy approaches for hematopoietic disorders. In 2014, she was appointed as a Lab Director at the Imagine Institute, where she pursued her studies on transcriptional regulation in normal and diseased stem cells, and their progeny. These basic research studies were instrumental in developing novel strategies for β-hemoglobinopathies. In particular, she optimized the design of a LV currently employed in a clinical trial for sickle cell disease and developed CRISPR/Cas9 strategies for β- hemoglobinopathies. 

Current positions: 

Since 2018 Permanent senior CR1 (1 st class charge de recherché) researcher. INSERM Unit UMR1163, France. 

Since 2014 Lab Director (laboratory of chromatin and gene regulation during development). Imagine Institute,  Paris Descartes University, INSERM Unit UMR1163, France.

T2EVOLVE Logo.png
bottom of page